Trial Profile
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2022
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Prednisone; Procarbazine
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 01 Feb 2022 Results published in the Leukemia
- 17 Jun 2021 Results of follow-up analysis of this randomized phase II study, presented at the 26th Congress of the European Haematology Association
- 26 Oct 2018 Status changed from active, no longer recruiting to completed.